psychedelics
(2)
CaaMTech
CaaMTech is an Issaquah, Washington drug discovery company building patentable, psychedelic-inspired medicines. Founded in 2016 by chemist and patent attorney Andrew Chadeayne, it has synthesized and characterized a large library of novel tryptamines, solved crystal structures of compounds like 4-AcO-DMT and norpsilocin, and filed more than 100 patent applications. The company studies the 'entourage effect' in magic mushrooms to engineer compounds that keep the benefits while reducing side effects, and in 2021 raised a $22M Series A to push lead candidates toward human trials.
Terran Biosciences
Terran Biosciences is a platform biotech developing therapeutics and technologies for neurological and psychiatric disease. It runs one of the industry's largest psychedelic development programs - psilocybin, LSD, MDMA derivatives and novel prodrugs - alongside late-stage schizophrenia assets licensed from Sanofi and Pierre Fabre, GMP psychedelic manufacturing, and NM-101, an FDA-cleared cloud platform for neuromelanin MRI analysis.